Peter H. O'Donnell to Polymorphism, Single Nucleotide
This is a "connection" page, showing publications Peter H. O'Donnell has written about Polymorphism, Single Nucleotide.
Connection Strength
1.209
-
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135.
Score: 0.373
-
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer. 2016 12; 14(6):511-517.
Score: 0.293
-
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73.
Score: 0.219
-
Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. J Appl Lab Med. 2021 11 01; 6(6):1505-1516.
Score: 0.108
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.098
-
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
Score: 0.053
-
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500.
Score: 0.053
-
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
Score: 0.012